Inhibrx, Inc.☆Watch⊞Compare

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Inhibrx, Inc. is one of 4291 Biotechnology companies tracked from LA JOLLA. By capital raised it ranks among the largest (ahead of 100% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst”

Inhibrx | Investors - Investors

No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic... Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing... Interim analyses show INBRX-106 + pembrolizumab achieved a 44.0% confirmed Objective Response Rate (cORR): In the preliminary confirmed response-evaluable population, the INBRX-106 + pembrolizumab... Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced... Title: The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study. Lead Author: Hans Gelderblom Abstract: 11504 Oral presentation: Saturday, May 30, 2026 (Session time: 4:12 PM – 4:24 PM CDT) Title: Phase 1 study of the tetravalent death receptor 5 agonist ozekibart (INBRX

As reported in public records reported — not modeled.

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Round size and date are reported; the stage label is inferred from round size (latest is Growth/Late — a round over $400M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Raised more than 100% of sector peers (real $). Modeled value above 97% of peers (estimate).

A tighter cohort than the sector chart above — only companies at the same stage (Growth/Late) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful.

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

1. Growth/Late$410.0M2018-04-30
   • First recorded raise — entered as Growth/Late.
   • 71 investors on this round.
2. Growth/Late$3.5M2018-05-04
   • Filed alongside the prior round (same month) — likely a tranche or amendment.
   • Round 115.5× smaller than the prior — bridge or down round.
   • 6 investors on this round.
3. Growth/Late$40.0M2019-05-20
   • Raised 13 mo later, in step with the ~14 mo sector norm.
   • Round 11.3× larger than the prior — scaling up.
   • 1 investor on this round.
4. Growth/Late$15.0M2020-04-06
   • Raised 11 mo later, in step with the ~14 mo sector norm.
   • Round 2.7× smaller than the prior — bridge or down round.
   • 5 investors on this round.
5. Growth/Late$200.0M2023-08-31
   • Raised again after 41 mo — slower than the ~14 mo sector norm.
   • Round 13.3× larger than the prior — scaling up.
   • 5 investors on this round.

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

Inhibrx, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

See where Inhibrx, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

If you work at Inhibrx, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.